ABSTRACT Fifty-four patients with evidence of locally advanced primary squamous cell bronchial carcinoma (SCC), and three patients with adenocarcinoma (AC) had 
control patients remained anergic after surgery. This improved immune reactivity went in parallel with a more favourable outcome of the individual patients (BCG-A, p<002; BCG-B, p<O 05). It 35 X 100 viable units of the vaccine into the thoracic cavity, by thoracentesis. In these cases, the vaccine was suspended in 2 ml of normal saline, and administered from five to seven days after operation. This dose was chosen after it had been shown that higher doses gave excessive sideeffects. In nine of the 14 patients isoniazid (300 mg/day) and pyridoxine (20 Figure 2 shows the "cumulative" percentage of tumour recurrence-free patients of the different BCG-treated groups and of the control patients, during the follow-up studies, and using the life- 
Discussion
The follow-up results, using BCG as a long-term adjuvant immunotherapy, confirmed earlier data. 4 A statistically significant prolongation of the re- 
